Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript

SA Transcripts 161.71K Followers Follow Insight Molecular Diagnostics Inc. ( IMDX ) Q2 2026 Earnings Call August 10, 2026 5:00 PM EDT Company Participants Gabrielle Woody - Sr. Executive Assistant Joshua Riggs - President, CEO & Director Andrea James - Chief Financial Officer Ekkehard Schutz - Chief Science Officer Conference Call Participants Mason Carrico - Stephens Inc., Research Division Mark Massaro - BTIG, LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Michael Matson - Needham & Company, LLC, Research Division Presentation Gabrielle Woody Sr. Executive Assistant Welcome, everyone, and thank you for joining us to discuss Insight Molecular Diagnostics' second quarter 2026 results. If you have not seen today's shareholder letter, please visit Insight Molecular Diagnostics' Investor Relations page at investors.imdxinc.com. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are Insight Molecular Diagnostics' President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Before turning the call over to Josh Riggs, I'd like to review our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's most recent Form 10-K and subsequent Form 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note the forward-looking statements made during today's call speak only to the date they are made, and Insight Molecular Diagnostics undertakes no obligation to update them. And with that, I would like to now turn the call over